Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

- Millennium on track to file sNDA in first quarter 2008 -

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly diagnosed multiple myeloma showed that the therapy of VELCADE, melphalan and prednisone (VMP) demonstrated a highly statistically significant improvement in all efficacy measures, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, compared to melphalan and prednisone (MP) alone. Based on the recommendation of an independent data monitoring committee (IDMC), which conducted the planned interim, the control arm of the trial was stopped early to allow patients still being treated with MP to have VELCADE added to their therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"These results position VELCADE based therapy as a new standard of care for newly diagnosed multiple myeloma patients," said Paul Richardson, M.D., Associate Professor of Medicine, Harvard Medical School; Clinical Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Boston; and a lead investigator of the VISTA trial. "The combination of VELCADE with melphalan and prednisone surpassed all efficacy endpoints, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, and did so, much earlier than expected. We are excited at the possibility this new therapy could be available to our patients sooner."

In the first
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... YORK, Sept. 9 New York Blood Center (NYBC), serving ... Island, the Hudson Valley and New Jersey, calls upon our ... and Labor Day holiday weekend have resulted in fewer donations ... B-negative blood for patients in need. Donations from ...
... Polycystic Ovarian Syndrome, known as PCOS, is a silent ... body and increases the risk of serious illness. ... and increases the risk of heart disease, insulin resistance, diabetes ... abnormality in women of child bearing age, affecting 5 to ...
Cached Medicine Technology:Blood Donors Needed as School, Fall Season Returns 2Blood Donors Needed as School, Fall Season Returns 3Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 3
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician ... practices; OB GYN in Melrose Park, IL and ... contains important information about each of the care services and ... forms in English and Spanish. The navigation of the ... the website provide Dr. Furlin’s patients with important information regarding ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... have newly identified 34 unique variations in the human ... sclerosis (ALS). ,The 34 so-called single nucleotide ... to the non-inherited form of the fatal neurodegenerative disease. ... responsible for sporadic ALS, our results seriously narrow the ...
... arteries and giving blood at six-monthly intervals to promote iron reduction ... ,A normal adult has five to six litres of blood ... blood donation. This blood is replaced by the body within 24 ... VA Medical Centre and the Dartmouth Medical School in Vermont looked ...
... for primary ciliary dyskinesia, a rare genetic disease that ... ,According to Thomas Ferkol, M.D., Washington University School of ... of patients with primary ciliary dyskinesia (PCD) have a ... of PCD requires a high index of suspicion, but ...
... such as Tenormin, Inderal and Lopressor should not be a ... a large new review of studies. ,The review, ... that beta-blocker users have a slightly higher risk of death ... such as Norvasc and Cardizem to manage their blood pressure. ...
... determined that low levels of a protein in the blood ... artery disease. ,In a group of men ... Activation, Normal T-cell Expressed, and Secreted), also known as CCL5, ... ,RANTES is a chemokine produced by a variety ...
... breast cancer prevention among women at high risk of the ... found that the breast cancer risk reduction persists long after ... to treat breast cancer and to prevent it among women ... data on tamoxifen for breast cancer prevention comes from the ...
Cached Medicine News:Health News:Human Genetic Code for ALS Identified 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3Health News:Beta-Blockers Should Not Be First Choice for High Blood Pressure 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: